Diabetes & metabolic syndromeJul 27, 2026

Changes in Eating Habits During Treatment with GLP-1 Receptor Agonists

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Aug 3, 2026

Abstract

GLP-1 receptor agonists, including tirzepatide, are associated with substantial weight loss.

The effect of GLP-1 receptor agonists on dietary intake during ad libitum lunch was evaluated.
Objective measurements of energy intake were utilized to assess the impact of these medications.
Findings may provide insights into how these treatments influence eating behaviors.

Simplified

Glucagon-like peptide-1 (GLP-1) receptor agonists, including the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide, produce substantial weight loss, yet their effect on objectively measured dietary intake has not been quantitatively synthesized. We assessed their impact on ad libitum lunch energy intake.

Full Text

Full text is available at the source.

View Full Text ↗

Weekly GLP-1 Therapies Brief

You found one interesting study. We’ll send the next 7.

Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.

What Lands in Your Inbox Each Week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the glp-1 therapies brief

Stop the drug, regain the weight: pooled data puts the average rebound at 7%

2 days ago7 studies

The brain region that explains why blocking and activating the same receptor both cause weight loss

1 week ago7 studies

GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study

2 weeks ago7 studies

Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients

3 weeks ago7 studies

Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study

4 weeks ago7 studies

Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients

5 weeks ago7 studies

Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group

6 weeks ago8 studies

New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients

7 weeks ago7 studies

GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery

8 weeks ago7 studies

Semaglutide linked to reduced cigarette craving in 24 smokers

9 weeks ago7 studies

explore the archive

See more issues from the glp-1 therapies brief